Literature DB >> 9891707

Radiologic diagnosis and pathology of the spondyloarthropathies.

J Braun1, M Bollow, J Sieper.   

Abstract

Five different subtypes of spondyloarthropathy (SpA) are now recognized. Clinical and radiologic involvement of the sacroiliac joint is an outstanding feature of the SpA, especially ankylosing spondylitis (AS). In this partly debilitating form of SpA a unique type of inflammatory axial involvement is observed which is characterized by inflammation and new bone formation at different spinal sites. In longstanding disease sacroiliitis, spondylitis and spondylodiscitis are easily recognized by conventional radiography and even better by computed tomography--especially when bony changes have already taken place. The advantage of dynamic magnetic resonance imaging (MRI) is to visualize morphologic changes and inflammation at the same time. This facilitates detection of sacroiliitis and spondylitis/spondylodiscitis at early time points. Hopefully, this will lead to other forms of therapy to prevent ankylosis of the spine. The origin of the granulation tissue infiltrating cartilage and bone in AS might be the synovium, the subchondrium or the bone marrow itself. T cells and macrophages seem to play an important role in this inflammatory process in which TNF-alpha is present in severe cases. The mechanisms responsible for the increased bone formation observed in the course of AS are unknown.

Entities:  

Mesh:

Year:  1998        PMID: 9891707     DOI: 10.1016/s0889-857x(05)70038-7

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  52 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors:  J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  HLA-DR4 and the spondyloarthropathies.

Authors:  J D Taurog
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 4.  New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Authors:  J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 5.  Pathogenesis of reactive arthritis.

Authors:  J Sieper
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

6.  Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems.

Authors:  J Braun; X Baraliakos; W Golder; K-G Hermann; J Listing; J Brandt; M Rudwaleit; S Zuehlsdorf; M Bollow; J Sieper; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

7.  Red blood cell distribution width: a potential maker estimating disease activity of ankylosing spondylitis.

Authors:  You-Fan Peng; Qiong Zhang; Ling Cao; Yang Liu; Dan Chen; Yu-Kun Sun; Zhao-Xia Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 8.  Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies.

Authors:  Giuseppe Guglielmi; Giacomo Scalzo; Alessia Cascavilla; Marina Carotti; Fausto Salaffi; Walter Grassi
Journal:  Clin Rheumatol       Date:  2009-06-13       Impact factor: 2.980

9.  [Spondylarthritides].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2006-11       Impact factor: 1.372

10.  BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondylitis show colony-dependent differences in disease penetrance.

Authors:  Balint Farkas; Ferenc Boldizsar; Oktavia Tarjanyi; Anna Laszlo; Simon M Lin; Gabor Hutas; Beata Tryniszewska; Aaron Mangold; Gyorgy Nagyeri; Holly L Rosenzweig; Alison Finnegan; Katalin Mikecz; Tibor T Glant
Journal:  Arthritis Res Ther       Date:  2009-02-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.